Research and Development Investment: Eli Lilly and Company vs Pharming Group N.V.

Eli Lilly vs Pharming: A Decade of R&D Growth

__timestampEli Lilly and CompanyPharming Group N.V.
Wednesday, January 1, 2014473360000014182353
Thursday, January 1, 2015479640000015503028
Friday, January 1, 2016524390000016183585
Sunday, January 1, 2017528180000022382849
Monday, January 1, 2018505120000033038206
Tuesday, January 1, 2019559500000031777040
Wednesday, January 1, 2020608570000041464134
Friday, January 1, 2021702590000067178053
Saturday, January 1, 2022719080000052531000
Sunday, January 1, 2023931340000068914000
Monday, January 1, 202414271000000
Loading chart...

Infusing magic into the data realm

A Decade of Innovation: R&D Investments in Pharmaceuticals

In the ever-evolving world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Eli Lilly and Company has consistently demonstrated its commitment to advancing medical science, with R&D expenses growing by nearly 97% from 2014 to 2023. In 2023 alone, Eli Lilly invested approximately $9.3 billion, a testament to its dedication to pioneering new treatments.

In contrast, Pharming Group N.V., while smaller in scale, has shown a steady increase in its R&D investments, growing by nearly 386% over the same period. This growth underscores the company's strategic focus on expanding its research capabilities.

These investments highlight the critical role of R&D in driving pharmaceutical advancements, ensuring that both companies remain at the forefront of medical innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025